BEIGENE,LTD.Files An 8-K Other Events
Item 8.01 Other Events
On June14, 2017, BeiGene,Ltd. (the Company) issued a press
release announcing updated clinical data from the ongoing Phase 1
trial of its Brutons Tyrosine Kinase (BTK) inhibitor BGB-3111 in
patients with chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL) in a poster at the 14th International
Conference on Malignant Lymphoma (14-ICML) in Lugano,
Switzerland. The full text of the Companys press release is filed
as Exhibit99.1 to this Current Report on Form8-K and is
incorporated herein by reference.
On June15, 2017, the Company issued a press release announcing
updated data from the ongoing Phase 1 trial of its BTK inhibitor
BGB-3111 in patients with Waldenstrms macroglobulinemia presented
at 14-ICML. The full text of the Companys press release is filed
as Exhibit99.2 to this Current Report on Form8-K and is
incorporated herein by reference.
On June16, 2017, the Company issued a press release announcing
initial clinical data from the ongoing Phase 1 trial of its BTK
inhibitor BGB-3111 combined with the anti-CD20 antibody
obinutuzumab in patients with CLL or SLL and follicular lymphoma
presented at 14-ICML. The full text of the Companys press release
is filed as Exhibit99.3 to this Current Report on Form8-K and is
incorporated herein by reference.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued on June14, 2017 |
|
|
99.2 |
Press Release issued on June15, 2017 |
|
|
99.3 |
Press Release issued on June16, 2017 |
***
BeiGene, Ltd. ExhibitEX-99.1 2 a17-15290_1ex99d1.htm EX-99.1 Exhibit 99.1 BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma CAMBRIDGE,…To view the full exhibit click here